Approach to Ventricular Arrhythmias¶
Chapter 259 | Part 6: Disorders of the Cardiovascular System
KEY CLINICAL POINTS¶
- Ventricular arrhythmias (VAs) range from benign to life-threatening, requiring differentiation between focal and reentrant mechanisms.
- Monomorphic VT is characterized by identical QRS morphology, while polymorphic VT shows changing morphology and is often associated with QT prolongation.
- ICD implantation is indicated for patients at risk of sudden cardiac death due to VT/VF, with programmed therapies including antitachycardia pacing and defibrillation.
- Catheter ablation is first-line for symptomatic VT with structural heart disease, targeting scarred or reentrant regions identified via electroanatomic mapping.
- Antiarrhythmic drugs like amiodarone and sotalol are used cautiously due to proarrhythmic risks, particularly in patients with QT prolongation.
1. DEFINITION & OVERVIEW¶
Ventricular arrhythmias (VAs) encompass premature ventricular beats (PVCs), ventricular tachycardia (VT), and ventricular fibrillation (VF). They arise from focal automaticity or reentrant circuits in the ventricles. VAs can be benign (e.g., isolated PVCs) or malignant (e.g., sustained VT/VF), requiring tailored management based on clinical context.
Table 258-3 Recommendations for Catheter Ablation in Patients with Atrial Fibrillation (AF)¶
| CLASS | LEVEL OF EVIDENCE | RECOMMENDATIONS |
|---|---|---|
| 1 | A | In patients with symptomatic AF in whom antiarrhythmic drugs have been ineffective, contraindicated, not tolerated, or not preferred, catheter ablation is useful to improve symptoms. |
| 1 | A | In patients with symptomatic or clinically significant atrial flutter, catheter ablation is useful for improving symptoms. |
| CLASS | LEVEL OF EVIDENCE | RECOMMENDATIONS |
|---|---|---|
| 2a | B | In patients (other than younger with few comorbidities) with symptomatic paroxysmal or persistent AF who are being managed with a rhythm-control strategy, catheter ablation as first-line therapy can be useful to improve symptoms. |
1.1 Types of Ventricular Arrhythmias¶
PVCs: Single ventricular beats occurring earlier than expected. Monomorphic VT: Three or more consecutive beats with identical QRS morphology. Polymorphic VT: Changing QRS morphology, often linked to QT prolongation. VF: Chaotic electrical activity with no discrete QRS complexes.
1.2 ECG Characteristics¶
PVCs show wide QRS (>0.12 s) with no preceding P wave. Monomorphic VT has a consistent QRS pattern, while polymorphic VT exhibits morphological variation. VF is characterized by irregular, chaotic waves without discernible QRS complexes.
2. EPIDEMIOLOGY¶
VAs are common in patients with structural heart disease (e.g., myocardial infarction, cardiomyopathy) and are associated with increased mortality. Risk factors include hypertension, ischemia, and electrolyte imbalances. PVCs are prevalent in healthy individuals, while sustained VT/VF is more common in patients with underlying cardiac disease.
2.1 Risk Factors¶
Structural heart disease, ischemia, electrolyte disturbances (e.g., hypokalemia), and genetic syndromes (e.g., Brugada syndrome) increase risk. Lifestyle factors like caffeine/alcohol may exacerbate arrhythmias.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
VAs arise from focal automaticity (e.g., Purkinje cells) or reentrant circuits in scarred myocardium. Monomorphic VT is often due to reentry in scarred tissue, while polymorphic VT is linked to QT prolongation (e.g., torsades de pointes). VF results from chaotic electrical activity without organized depolarization.
4. CLINICAL FEATURES¶
Symptoms include palpitations, dizziness, syncope, and sudden cardiac arrest. Asymptomatic VAs may be detected incidentally on ECG. Sustained VT/VF can present with hypotension, hemodynamic instability, or cardiac arrest.
4.1 Syncope¶
Syncope in the absence of structural heart disease may indicate idiopathic VT. In patients with structural disease, syncope may reflect hemodynamic compromise from VT.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses include supraventricular tachycardia (SVT) with aberrancy, atrial fibrillation with rapid ventricular response, and electrolyte disturbances. ECG morphology and clinical context are critical for differentiation.
5.1 ECG Differentiation¶
Monomorphic VT is distinguished from SVT with aberrancy by the presence of a consistent QRS morphology and absence of P waves. VF is characterized by chaotic electrical activity without organized waves.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis relies on ECG findings, ambulatory monitoring, and cardiac imaging. Electroanatomic mapping identifies arrhythmia substrates for ablation. Cardiac MRI detects scar tissue in patients with VT.
ECG Findings for Ventricular Arrhythmias¶
| Arrhythmia Type | QRS Morphology | Rate | ECG Features |
|---|---|---|---|
| PVCs | Wide QRS (>0.12 s) | Variable | No preceding P wave, attenuated arterial pressure |
| Monomorphic VT | Consistent QRS pattern | 100–250 bpm | No P waves, regular rhythm |
| Polymorphic VT | Changing QRS morphology | 100–250 bpm | QT prolongation, torsades de pointes |
| VF | Chaotic waves | >250 bpm | No discernible QRS complexes |
6.1 Diagnostic Criteria¶
Monomorphic VT is diagnosed by three or more consecutive beats with identical QRS morphology. VF is confirmed by continuous irregular electrical activity without discernible QRS complexes.
7. MANAGEMENT & TREATMENT¶
Management depends on arrhythmia type and patient risk. Antiarrhythmics (e.g., amiodarone), ICD implantation, and catheter ablation are primary interventions. Lifestyle modifications and risk factor reduction are critical for prevention.
Treatment Algorithms for Ventricular Arrhythmias¶
| Clinical Scenario | Initial Management | Long-Term Strategy |
|---|---|---|
| Asymptomatic PVCs | Reassurance, avoid triggers | Monitor for progression |
| Symptomatic VT with structural disease | Catheter ablation | ICD implantation for high-risk patients |
| VF with hemodynamic instability | Immediate defibrillation | ICD implantation |
7.1 Antiarrhythmic Drugs¶
Amiodarone is first-line for acute VT/VF. Sotalol and dofetilide are used cautiously in patients without QT prolongation. β -blockers are effective for idiopathic VT and exercise-induced arrhythmias.
7.2 ICD Therapy¶
ICDs terminate VT/VF via antitachycardia pacing or defibrillation. Programming adjustments are required for patients with recurrent arrhythmias or drug-induced proarrhythmia.
7.3 Catheter Ablation¶
Radiofrequency ablation targets scarred or reentrant regions identified via electroanatomic mapping. Success rates are higher for idiopathic VT than for scar-related VT.
8. PROGNOSIS & COMPLICATIONS¶
Prognosis varies by arrhythmia type and underlying disease. Sustained VT/VF is associated with high mortality, while isolated PVCs are generally benign. Complications include sudden cardiac death, drug-induced proarrhythmia, and ICD-related adverse events.
8.1 Sudden Cardiac Death¶
Patients with structural heart disease and recurrent VT/VF are at highest risk. ICDs reduce mortality by 30–50% in high-risk populations.
9. SPECIAL CONSIDERATIONS¶
Pregnancy requires careful management of antiarrhythmics and ICD use. Pediatric patients may present with idiopathic VT or congenital arrhythmias. Elderly patients are at higher risk for drug toxicity and hemodynamic instability.
9.1 Genetic Syndromes¶
Long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic VT require genetic testing and specialized management.
10. KEY POINTS & CLINICAL PEARLS¶
- Differentiate VAs from SVT using ECG morphology and clinical context. 2. ICDs are indicated for patients with structural heart disease and recurrent VT/VF. 3. Catheter ablation is first-line for symptomatic VT with structural disease. 4. Antiarrhythmics carry proarrhythmic risks and should be used cautiously. 5. Monitor for electrolyte imbalances and drug interactions in patients with VAs.